Immune Modulation, Inc.

Immune Modulation, Inc. (IMI) is a biomedical startup that has developed a groundbreaking plant-based drug with vast potential to combat endemic diseases. IMI has harnessed the power of natural medicine to create a pharmaceutical agent with remarkable anti-malarial, anti-inflammatory, anti-viral, and anti-parasitic properties. Established in 1995, the company is headquartered in the United States and operates in the Biotechnology and Health Care industries. The team at IMI comprises accomplished Research Scientists and Medical Practitioners, driven by their mission to address global, unmet medical needs through the development of novel pharmaceutical, nutraceutical, and cosmetic agents derived from natural bio-resources. This innovative approach aims to provide orally bio-available, non-toxic therapeutics, ultimately altering the global healthcare landscape. Investors and funding details were not provided at this time.